A new market research report by Transparency Market Research, titled “Ulcerative Colitis Therapeutics Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019,” presents an extensive analysis of the market. The report helps in identifying the major trends driving and shaping the growth of the market. The study also encapsulates the competitive landscape and presents valuable insights on the pipeline products in the market for ulcerative colitis therapeutics market. A review has been provided on the micro and macro factors benefiting the existing players and the upcoming players in the market. The report helps in understanding and identifying the diverse and important kinds of therapeutics still under development to treat ulcerative colitis.
Download Complete For This Report Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2185
The report starts by providing the definition and symptoms of ulcerative colitis. Ulcerative colitis is a type of inflammatory bowel disease causing ulcers and inflammation in the colon, the biggest part of the large intestine, either partially or completely. The prime symptom of an active disease includes diarrhea and blood. This disease can sometimes result in life-threatening complications owing to the fact that it is a result of the abnormal response of the immune system. It is primarily prevalent in the age group ranging from 15 to 30 years. As per the report, at present there is no known cure for this disease; however, the launch of new therapeutics may offer symptomatic treatment options.
In terms of drug class, the report segments the market for ulcerative colitis therapeutics into aminosalicylates, corticosteroids, immune modulators, antibiotics, and others. The segment of aminosalicylates is further segmented into sulfasalazine, balsalazide, and mesalamine. The segment of corticosteroids is further segmented into prednisone and methylprednisolone while the segment of antibiotics is further segmented into ciprofloxacin and ampicillin. Factors such as the high sales of the already existing drugs and the strong pipeline of therapeutic products will stimulate the growth of the market.
The report states that some of the recently launched FDA-approved drugs for the treatment of ulcerative colitis include SIMPONI ARIA, an infusion treatment by Janssen Biotech, Inc. This drug was launched in July 2013. Santarus Inc. launched UCERIS in January 2013 while Warner Chilcott introduced DELZICOL in April 2013.
In terms of geography, the report segments the market into Asia Pacific, North America, Europe, and Rest of the World (RoW). North America, Northern Europe, and the UK have reported the highest ulcerative colitis cases in the past few years, as per the U.S Pharmacist. As stated in the report, the key manufacturers operating in the market are Johnson & Johnson, Takeda Pharmaceutical Company, Janssen Biotech, Inc., Abbott Laboratories, and Pfizer Inc., among others.
Access Full Report With TOC: http://www.transparencymarketresearch.com/ulcerative-colitis-therapeutics-market.html